---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-24-000062"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:37:17.839967+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Exelixis sues Cipla over generic Cabometyx patents covering 20mg, 40mg strengths

## Summary
- Cipla amended its ANDA to seek approval for 20mg and 40mg generic cabozantinib, adding Paragraph IV certifications.
- Exelixis filed a patent infringement complaint on May 9, 2024 in Delaware federal court.
- Five patents asserted: U.S. Patent Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, 11,298,349.
- Exelixis seeks order that FDA approval be no earlier than the latest patent expiration on February 10, 2032.

## SEC filing metadata
- accession: 0000939767-24-000062
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976724000062/0000939767-24-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976724000062/exel-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-24-000062
- JSON: https://secwatch.observer/filing/0000939767-24-000062.json
- Plain text: https://secwatch.observer/filing/0000939767-24-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.